Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

A. John Camm; Craig M. Pratt; Peter J. Schwartz; Hussein R. Al-Khalidi; Maria J. Spyt; Michael J. Holroyde; Roger Karam; Edmund H. Sonnenblick; Jose M G Brum

doi:10.1161/01.CIR.0000117090.01718.2A

Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

A. John Camm, Craig M. Pratt, Peter J. Schwartz, Hussein R. Al-Khalidi, Maria J. Spyt, Michael J. Holroyde, Roger Karam, Edmund H. Sonnenblick, Jose M G Brum

Fondazione Istituto Auxologico Italiano

Research output: Contribution to journal › Article › peer-review

Abstract

Background - Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results - A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P

Original language	English
Pages (from-to)	990-996
Number of pages	7
Journal	Circulation
Volume	109
Issue number	8
DOIs	https://doi.org/10.1161/01.CIR.0000117090.01718.2A
Publication status	Published - Mar 2 2004

Keywords

Antiarrhythmia agents
Azimilide
Heart rate
Trials

ASJC Scopus subject areas

Physiology
Cardiology and Cardiovascular Medicine

Access to Document

10.1161/01.CIR.0000117090.01718.2A

Cite this

Camm, A. J., Pratt, C. M., Schwartz, P. J., Al-Khalidi, H. R., Spyt, M. J., Holroyde, M. J., Karam, R., Sonnenblick, E. H., & Brum, J. M. G. (2004). Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification. Circulation, 109(8), 990-996. https://doi.org/10.1161/01.CIR.0000117090.01718.2A

Mortality in Patients after a Recent Myocardial Infarction : A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification. / Camm, A. John; Pratt, Craig M.; Schwartz, Peter J.; Al-Khalidi, Hussein R.; Spyt, Maria J.; Holroyde, Michael J.; Karam, Roger; Sonnenblick, Edmund H.; Brum, Jose M G.

In: Circulation, Vol. 109, No. 8, 02.03.2004, p. 990-996.

Research output: Contribution to journal › Article › peer-review

Camm, AJ, Pratt, CM, Schwartz, PJ, Al-Khalidi, HR, Spyt, MJ, Holroyde, MJ, Karam, R, Sonnenblick, EH & Brum, JMG 2004, 'Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification', Circulation, vol. 109, no. 8, pp. 990-996. https://doi.org/10.1161/01.CIR.0000117090.01718.2A

Camm, A. John ; Pratt, Craig M. ; Schwartz, Peter J. ; Al-Khalidi, Hussein R. ; Spyt, Maria J. ; Holroyde, Michael J. ; Karam, Roger ; Sonnenblick, Edmund H. ; Brum, Jose M G. / Mortality in Patients after a Recent Myocardial Infarction : A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification. In: Circulation. 2004 ; Vol. 109, No. 8. pp. 990-996.

@article{fc8c4519bfe44d80a1eee30914877eec,

title = "Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification",

abstract = "Background - Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results - A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P",

keywords = "Antiarrhythmia agents, Azimilide, Heart rate, Trials",

author = "Camm, {A. John} and Pratt, {Craig M.} and Schwartz, {Peter J.} and Al-Khalidi, {Hussein R.} and Spyt, {Maria J.} and Holroyde, {Michael J.} and Roger Karam and Sonnenblick, {Edmund H.} and Brum, {Jose M G}",

year = "2004",

month = mar,

day = "2",

doi = "10.1161/01.CIR.0000117090.01718.2A",

language = "English",

volume = "109",

pages = "990--996",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Mortality in Patients after a Recent Myocardial Infarction

T2 - A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

AU - Camm, A. John

AU - Pratt, Craig M.

AU - Schwartz, Peter J.

AU - Al-Khalidi, Hussein R.

AU - Spyt, Maria J.

AU - Holroyde, Michael J.

AU - Karam, Roger

AU - Sonnenblick, Edmund H.

AU - Brum, Jose M G

PY - 2004/3/2

Y1 - 2004/3/2

N2 - Background - Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results - A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P

AB - Background - Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results - A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P

KW - Antiarrhythmia agents

KW - Azimilide

KW - Heart rate

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=1442335812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442335812&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000117090.01718.2A

DO - 10.1161/01.CIR.0000117090.01718.2A

M3 - Article

C2 - 14967728

AN - SCOPUS:1442335812

VL - 109

SP - 990

EP - 996

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -

Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this